A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

NCT04689204 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Non-hodgkin Lymphoma

Interventions

DRUG: CTA30X

Sponsor

He Huang

Collaborators

[object Object]